Related coverage linked through entity extraction aliases.
May 02, 2026
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Mar 25, 2026
New research challenges the theory that ketamine's psychedelic effects drive its therapeutic benefits for alcohol use disorder. A study of 96 participants found no link between ketamine's psychoactive experiences and improved abstinence rates. The findings suggest other mechanisms, such as brain network alterations, may explain ketamine's effectiveness in treating addiction.
Feb 26, 2026
Early trial of Rezatapopt shows 20% response rate in advanced cancers with p53 mutations, while researchers identify AMD3100 as potential solution to enable immunotherapy in rare liver cancer.
Feb 13, 2026
Global pharmaceutical companies are accelerating licensing deals for China-developed experimental medicines, with deal values reaching unprecedented levels in 2026 as firms cut costs ahead of patent expirations.
Sep 11, 2025
The FDA issued a Complete Response Letter for Corcept's relacorilant as a treatment for hypertension secondary to hypercortisolism, requesting additional evidence of effectiveness despite acknowledging positive trial results.
